Zivo Bioscience, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 14, 2023 and accepted by EDGAR at Aug 14, 2023, 16:17 ET.
Management's discussion and analysis
As filed, 29,970 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements contained in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements regarding:
- our ability to raise the funds we need to continue our operations;
- our goal to generate revenues and become profitable;
- regulation of our product;
- market acceptance of our product and derivatives thereof;
- the results of current and future testing of our product;
- the anticipated performance and benefits of our product;
- the ability to generate licensing fees; and
- our financial condition or results of operations.
In some cases, you can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “projects”, “predicts”, “potential” and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.
Overview:
We are a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health.
Biotech - ZIVO Product Candidates
ZIVO is developing bioactive compounds derived from its proprietary algal culture, targeting human and animal diseases, such as poultry coccidiosis, bovine mastitis, human cholesterol, and canine osteoarthritis. As part of its strategy, ZIVO will continue to seek strategic partners for late stage development, regulatory preparation and commercialization of its products in key global markets.
Review of isolated active materials derived from our proprietary algal culture and their potential treatment applications led us to identify a product candidate for treating coccidiosis in broiler chickens as the best option for most rapidly generating significant revenue because coccidiosis is a global poultry industry issue, and because the clinical testing cycle for chickens is shorter than for other species. Most of the global animal health companies have products for the coccidiosis market; however, they are mostly antibiotic- or ionophore-based with essentially no new technology having been introduced in the last 60 years.
16
Table of Contents
Agtech - ZIVO’s Algal Biomass
ZIVO’s algal biomass is currently produced in Peru. ZIVO’s algal biomass contains Vitamin A, protein, iron, important fatty acids, non-starch polysaccharides and other micronutrients that position the product as a viable functional food ingredient and nutritional enhancement for human and animal use and as a viable functional ingredient for skin care products.
Through our direction and technology, a site in Peru has been successful in consistently producing our proprietary algae. Our team has been working toward building commercial-scale algae ponds using a ZIVO proprietary design, and we are in the middle of a project to grow our algae in a penultimate scale pond. Once we are successful at this scale, we plan to invest in full commercial-scale ponds and product processing equipment.
The Company currently has contracts for the sale and production of its algal biomass. ZIVO has engaged an independent distributor, ZWorldwide, Inc., who has begun to sell the product, branded ZivolifeTM, with an initial focus on the North American green powder food market with the product being grown in Peru.
Additional Indications
Pending additional funding, ZIVO may also pursue the following indications:
Biotech:
- Bovine Mastitis: ZIVO is developing a treatment for bovine mastitis derived from its proprietary algal culture and the bioactive agents contained within.
- Canine Joint Health: Studies have indicated the potential of a chondroprotective property when a compound fraction was introduced into ex vivo canine joint tissues.
- Human Immune Modulation: Early human immune cell in vitro and in vivo studies have indicated that one of the isolated and characterized biologically active molecules in the Company’s portfolio may serve as an immune modulator with potential application in multiple disease situations
Agtech:
- Human Food Ingredient: The self-affirmed GRAS process was completed for ZIVO algal biomass in late 2018 to validate its suitability for human consumption as an ingredient in foods and beverages.
- Skin Health: ZIVO is developing its algal biomass as a skin health ingredient, with topical skin product testing started in the third quarter of 2020, and clinical efficacy claim studies planned for ingestible and topical products.
Recent Developments
June 2023 Registered Direct Offering and Private Placement
On June 30, 2023, the Company sold 1,030,000 shares of common stock, par value $0.001 per share, at an offering price of $2.67 per share, and pre-funded warrants to purchase up to an aggregate of 468,130 shares of Common Stock at an offering price of $2.6699 per pre-funded warrant, to a single institutional investor. In a concurrent private placement, the Company also directly sold to the purchaser Series A Common Warrants to purchase up to an aggregate of 1,498,130 shares of common stock, at an exercise price of $2.80 per share and Series B Common Warrants to purchase up to an aggregate of 1,498,130 shares of Common Stock, at an exercise price of $2.80 per share. The Series A Common Warrants are immediately exercisable, subject to a beneficial ownership limitation of the holder provided in the Series A Common Warrants, at any time on or after the date of issuance and will expire two years from the initial exercise date. The Series B Common Warrants are immediately exercisable, subject to a beneficial ownership limitation of the holder provided in the Series B Common Warrants, at any time on or after the date of issuance and will expire five years from the initial exercise date. The gross proceeds to the Company from the registered direct offering and concurrent private placement were $3,999,960 (before deducting the placement agent’s fees and other estimated offering expenses payable by the Company). Net proceeds to the Company were $3,634,963.
17
Table of Contents
Results of Operations for the three months ended June 30, 2023 and 2022
The following table summarizes ZIVO’s operating results for the periods indicated:
| Quarter ended June 30, 2023 | 2022 | |
|---|---|---|
| Total revenue: | $4,050 | $- |
| Total cost of goods sold | 701 | - |
| Gross margin | 3,349 | - |
| Costs and expenses: | ||
| Research and development | 442,113 | 438,048 |
| General and administrative | 1,385,102 | 1,629,553 |
| Total costs and expenses | 1,827,215 | 2,067,601 |
| Loss for operations | (1,823,866) | (2,067,601) |
| Other expense: | ||
| Total other income, net | (246,706) | (4,238) |
| Net loss | $(2,070,572) | $(2,071,839) |
Revenue
During the three months ended June 30, 2023, the Company recorded its first commercial revenue relating to sales of the Company’s dried algal biomass product as a human food or food ingredient. The $4,000 for the quarter ending June 30, 2023 is an increase over the $0 in revenue in the same quarter in the comparable prior year. The $4,000 increase is the result of no recorded revenue in the three months ended June 30, 2022.
Costs of Goods Sold
Cost of goods sold for the quarter ended June 30, 2023 was $700. This is $700 higher than the same period last year, attributable to product volume as no product was shipped in the comparable prior year period.
General and Administrative Expenses
General and administrative expenses were approximately $1.4 million for the three months ended June 30, 2023, as compared to approximately $1.6 million for the comparable prior year period. The decrease of approximately $250,000 in general and administrative expense during 2023 is due primarily to a reduction in labor related expenses of approximately $100,000, lower professional services of approximately $180,000, partially offset by an increase in other overhead of $30,000. The reduction in labor related costs are exclusively the result of lower non-cash compensation expense versus the first quarter of 2022. Lower professional fees were driven by lower directors’ fees of approximately $140,000 and a reduction in spending on consultants of $40,000. The increase in other overhead spending is attributable to higher listing and filing fees of $30,000.
Research and Development Expenses
For the three months ended June 30, 2023, the Company incurred approximately $440,000 in research and development expenses, as compared to approximately $440,000 for the comparable period in 2022. All of these expenses were associated with research relating to our biotech and agtech businesses. In the quarter ended June 30, 2023, the Company’s research and development spending included approximately $309,400 of amortization of deferred research and development obligations for the participation agreements; there was no amortization of deferred research and development in the comparable prior year period.
18
Table of Contents
In the quarter ended June 30, 2023, excluding this amortization, the Company had gross research and development spending of approximately $750,000; a $40,000 increase in spending from the second quarter of 2022. Of these costs in the second quarter of 2023, $320,000 was attributable to labor and other internal research and development costs, a decrease of approximately $20,000 from the comparable prior year. The decrease is entirely the result of lower non-cash compensation related costs. Third party research and development spending of $430,000 was approximately $60,000 higher than the comparable prior year period due to an increase in third party research studies.
| Quarter ended June 30, 2023 | Quarter ended June 30, 2022 | |
|---|---|---|
| Labor and other internal expenses | $326,755 | $347,726 |
| External research expenses | 424,758 | 360,558 |
| Total gross R&D expenses | 751,513 | 708,284 |
| Less contra-expense for amortization of deferred R&D obligation - participation agreements | (309,400) | (270,237) |
| Research and development | $442,113 | $438,048 |
Results of Operations for the six months ended June 30, 2023 and 2022
The following table summarizes ZIVO’s operating results for the periods indicated:
| Six Months ended June 30, 2023 | 2022 | |
|---|---|---|
| Total revenue: | $4,050 | $- |
| Total costs of goods sold | 701 | - |
| Gross margin | 3,349 | |
| Costs and expenses: | ||
| Research and development | 843,910 | 1,117,821 |
| General and administrative | 2,953,478 | 2,976,295 |
| Total costs and expenses | 3,797,388 | 4,094,116 |
| Operating loss | (3,794,039) | (4,094,116) |
| Other income (expense): | ||
| Total other income, net | (249,675) | (6,043) |
| Net loss | $(4,043,714) | $(4,100,159) |
Revenue
In the six months ended on June 30, 2023 the Company recorded its first commercial revenue relating sales of the Company’s dried algal biomass product as a human food or food ingredient. The $4,000 for the six months ending June 30, 2023 is an increase over the $0 in revenue in the same six month period ended June 30, 2022. The $4,000 increase is the result of no recorded revenue in the six months ended June 30, 2022.
Costs of Goods Sold
Cost of goods sold for the six months ended June 30, 2023 was $700. This is $700 higher than the same period last year,as no product was shipped in the prior year period.
General and Administrative Expenses
General and administrative expenses were $3.0 million for the six months ended June 30, 2023, in line with the $3.0 million in the comparable prior year period. The decrease of approximately $20,000 in general and administrative expense during 2023 is explained by higher labor related costs of approximately $100,000 and $70,000 of other overhead, more than offset by a reduction in professional fees of $200,000. The $100,000 increase in labor related expenses is attributable to an increase in salary cost of $180,000 partially offset by reductions in tax and benefits of $40,000 and non-cash compensation of $30,000. Other overhead increases are due to a $40,000 increase in insurance costs and a $30,000 increase in filing and listing fees. The reduction in professional service is attributable to a $100,000 reduction in third party consultant spending and lower directors’ fees of approximately $400,000, partially offset by an increase in legal and accounting fees of $300,000.
19
Table of Contents
Research and Development Expenses
For the six months ended June 30, 2023, the Company incurred approximately $840,000 in research and development expenses, as compared to approximately $1.1 million in the comparable period in 2022. All of these expenses were associated with research relating to our biotech and agtech businesses. In the six months ended June 30, 2023, the Company’s research and development spending included approximately $430,000 of amortization of deferred research and development obligations for the participation agreements; there was no amortization of deferred research and development in the comparable prior year period.
In the six months ended June 30, 2023, excluding this amortization, the Company had gross research and development spending of approximately $1.3 million; a $240,000 decrease in spending from the first half of 2022. Of these costs in the first half of 2023, approximately $660,000 was related to labor and other internal lab costs, a decrease of approximately $180,000 from the comparable prior year, primarily attributable to a decrease in non-cash compensation. Third party research and development spending of $610,000 was approximately $50,000 lower from the comparable prior year period.
| Six months ended June 30, 2023 | Six months ended June 30, 2022 | |
|---|---|---|
| Labor and other internal expenses | $664,667 | $859,623 |
| External research expenses | 613,673 | 665,283 |
| Total gross R&D expenses | 1,278,340 | 1,524,906 |
| Less contra-expense for amortization of deferred R&D obligation - participation agreements | (434,430) | (407,085) |
| Research and development | $843,910 | $1,117,821 |
Capital Resources
As of June 30, 2023, ZIVO’s principal source of liquidity consisted of cash of $21,067. The Company expects to continue to incur significant expenses and increasing operating and net losses for the foreseeable future until and unless we generate an adequate level of revenue from potential commercial sales to cover expenses. The sources of cash to date have been limited proceeds from the issuances of notes with warrants, common stock with and without warrants and unsecured loans, with the terms of our most recent financings described below.
June 2023 Registered Direct Offering and Private Placement
On June 30, 2023, the Company sold 1,030,000 shares of common stock, par value $0.001 per share, at an offering price of $2.67 per share, and pre-funded warrants to purchase up to an aggregate of 468,130 shares of Common Stock at an offering price of $2.6699 per pre-funded warrant, to a single institutional investor. In a concurrent private placement, the Company also directly sold to the purchaser Series A Common Warrants to purchase up to an aggregate of 1,498,130 shares of common stock, at an exercise price of $2.80 per share and Series B Common Warrants to purchase up to an aggregate of 1,498,130 shares of Common Stock, at an exercise price of $2.80 per share. The Series A Common Warrants are immediately exercisable, subject to a beneficial ownership limitation of the holder provided in the Series A Common Warrants, at any time on or after the date of issuance and will expire two years from the initial exercise date. The Series B Common Warrants are immediately exercisable, subject to a beneficial ownership limitation of the holder provided in the Series B Common Warrants, at any time on or after the date of issuance and will expire five years from the initial exercise date. The gross proceeds to the Company from the registered direct offering and concurrent private placement were approximately $4,000,000.00 (before deducting the placement agent’s fees and other estimated offering expenses payable by the Company).
20
Table of Contents
Participation Agreements
From April 13, 2020, through May 14, 2021, the Company entered into twenty-one License Co-Development Participation Agreements (the “Participation Agreements”) with certain accredited investors (“Participants”) for an aggregate of $2,985,000 in proceeds. The Participation Agreements provide for the issuance of warrants to such Participants and allows the Participants to participate in the fees (the “Fees”) from licensing or selling bioactive ingredients or molecules derived from ZIVO’s algae cultures. Specifically, ZIVO has agreed to provide to the Participants a 44.775% “Revenue Share” of all license fees generated by ZIVO from any licensee.
The Participation Agreements allow the Company the option to buy back the right, title and interest in the Revenue Share for an amount equal to the amount funded plus a forty percent (40%) premium, if the option is exercised less than 18 months following execution, and for either forty (40%) or fifty percent (50%) if the option is exercised more than 18 months following execution. Pursuant to the terms of twelve of the Participation Agreements, the Company may not exercise its option until it has paid the Participants a revenue share equal to a minimum of thirty percent (30%) of the amount such Participant’s total payment amount. Pursuant to the terms of the one of the Participation Agreements, the Company may not exercise its option until it has paid the Participant a revenue share equal to a minimum of one hundred forty percent (140%) of the amount such Participant’s total payment amount. Five of the Participation Agreements have no minimum threshold payment. Once this minimum threshold is met, the Company may exercise its option by delivering written notice to a Participant of its intent to exercise the option, along with repayment terms of the amount funded, which may be paid, in the Company’s sole discretion, in one lump sum or in four (4) equal quarterly payments. If the Company does not make such quarterly payments timely for any quarter, then the Company shall pay the prorate Revenue Share amount, retroactive on the entire remaining balance owed, that would have been earned during such quarter until the default payments have been made and the payment schedule is no longer in default.
Funding Requirements
Management has noted the existence of substantial doubt about our ability to continue as a going concern. Our existing cash may not be sufficient to fund our operating expenses through at least twelve months from the date of this filing. To continue to fund operations, we will need to secure additional funding through public or private equity or debt financings, through collaborations or partnerships with other companies or other sources. We may not be able to raise additional capital on terms acceptable to us, or at all. Any failure to raise capital when needed could compromise our ability to execute on our business plan. If we are unable to raise additional funds, or if our anticipated operating results are not achieved, we believe planned expenditures may need to be reduced in order to extend the time period that existing resources can fund our operations. If we are unable to obtain the necessary capital, it may have a material adverse effect on our operations and the development of our technology, or we may have to cease operations altogether.
Our material cash requirements relate to the funding of our ongoing product development. The development of our product candidates is subject to numerous uncertainties, and we could use our cash resources sooner than we expect. Additionally, the process of development is costly, and the timing of progress in pre-clinical tests and clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving further regulatory approvals and achieving a level of product sales adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.
Statement of Cash Flows
Cash Flows from Operating Activities. During the six months ended June 30, 2023, our operating activities used $3.1 million in cash, a decrease of cash used of approximately $1.1 million from the comparable prior year period when the Company used approximately $4.2 million for operating activities. After adjusting the comparison period’s net income for non-cash expenses including equity-based compensation and amortization of lease liabilities, the Company incurred approximately $60,000 less of additional net loss than in the comparable prior year period. In addition, for the six months ended June 30, 2023, the Company generated about $1.4 million of cash through increases in accounts payables and accrued expenses.
21
Table of Contents
Cash Flows from Investing Activities. During the six months ended June 30, 2023 and 2022, there were no investing activities.
Cash Flows from Financing Activities. During the six months ended June 30, 2023, our financing activities generated approximately $1.3 million, an increase of approximately $900,000 from the comparable prior year period when the Company generated approximately $350,000 from financing activities. In the six months ended June 30, 2023, the Company received net proceeds of $1.0 million from a term loan provided by a related party to the Company, which fully accounts for the change from the comparable prior year period.
After giving effect to the approximately $3.7 million in net proceeds from the June 2023 Registered Direct Offering received on July 5, 2023, we estimate that we would require approximately $2.0 million in cash over the next 12 months in order to fund our basic operations, excluding our research and development initiatives. Based on this cash requirement, we have a near term need for additional funding to continue to develop our products and intellectual property. Historically, we have had substantial difficulty raising funds from external sources. If we are unable to raise the required capital, we will be forced to curtail our business operations, including our research and development activities. The following table shows a summary of our cash flows for the periods indicated:
| Net cash provided by (used in): | Six months ended June 30, 2023 | 2022 |
|---|---|---|
| Operating activities | $(3,114,640) | $(4,167,376) |
| Investing activities | - | - |
| Financing activities | 1,336,444 | 349,222 |
| Net increase (decrease) in Cash | $(1,778,196) | $(3,818,154) |
Critical Accounting Policies and Significant Judgments and Estimates
Critical Accounting Policies
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date of the change in estimate.
While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Report, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments.
Fair Value of Financial Instruments
We account for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis adhering to the Financial Accounting Standards Board (“FASB”) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:
22
Table of Contents
Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.
Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
As of June 30, 2023 and 2022, fair values of cash, prepaid, other assets, accounts payable and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. We elected to account for the convertible notes while they were outstanding on a fair value basis under ASC 825 to comprehensively value and streamline the accounting for the embedded conversion options. The fair value of these convertible notes were based on both the fair value of our common stock, discount associated with the embedded redemption features, and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs.
Complex Financial Instruments
We evaluate all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. As the Warrants issued in the quarter ended June 30, 2023 are classified as equity, then the proceeds should be allocated based on the relative fair values of the base instrument and the warrants following the guidance in ASC 470, Debt. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated embedded derivative is accounted for separately on a fair market value basis. We record the fair value changes of a separated embedded derivative at each reporting period in the consolidated statements of comprehensive loss as a fair value change in derivative and warrant liabilities.
Stock-Based Compensation
We account for share‑based compensation in accordance with the provisions of the ASC 718, Compensation - Stock Compensation. Accordingly, compensation costs related to equity instruments granted are recognized at the grant‑date fair value. The Company records forfeitures when they occur. Share‑based compensation arrangements to non‑employees are accounted for in accordance with the applicable provisions of ASC 718.
Recent Accounting Pronouncements
See “Note 2 - Summary of Significant Accounting Policies” in this Report regarding the impact of certain recent accounting pronouncements on our financial statements.
Controls and procedures
As filed, 7,639 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, to allow timely decisions regarding disclosure. The Chief Executive Officer and the Chief Financial Officer, as our principal financial and accounting officer, have reviewed the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q and, based on their evaluation, have concluded that the disclosure controls and procedures were not effective as the material weaknesses identified as of December 31, 2022 and described below, continue to exist as of June 30, 2023.
23
Table of Contents
Material Weaknesses in Internal Control Over Financial Reporting
Management has determined that the Company had the following material weaknesses in its internal control over financial reporting:
Control Environment, Risk Assessment, and Monitoring
Management did not design and maintain appropriate entity-level controls impacting the control environment, risk assessment procedures, and monitoring activities to prevent or detect material misstatements to the consolidated financial statements. These deficiencies were attributed to: (i) lack of structure and responsibility, insufficient number of qualified resources, and inadequate oversight and accountability over the performance of controls, (ii) ineffective identification and assessment or risks impacting internal control over financial reporting, and (iii) ineffective evaluation and determination as to whether the components of internal control were present and functioning.
Control Activities and Information and Communication
These material weaknesses contributed to the following additional material weaknesses within certain business processes and the information technology environment:
- Management did not design and maintain appropriate information technology general controls in the areas of user access, vendor management controls, and segregation of duties, including controls over the recording and review of journal entries, related to certain information technology systems that support the Company’s financial reporting process.
- Management did not design, implement, and retain appropriate documentation of formal accounting policies, procedures, and controls across substantially all of the company's business processes over; (i) the financial reporting process, including management review controls over key disclosures and financial statement support schedules, (ii) the monthly financial close process, including journal entries and account reconciliations and (iii) the completeness and accuracy of information used by control owners in the operation of certain controls, to achieve timely, complete, accurate financial accounting, reporting.
- Management did not design and implement controls over the accounting, classification, and application of United States Generally Accounting Principles (“US GAAP”) relating to income taxes, stock-based compensation, and deferred research and development obligations - participation agreements accounting. Specifically:
- Management did not identify controls over the review of the tax provision, including the valuation analysis related to deferred tax assets, considerations for uncertain tax positions, the preparation of the income tax footnote and required disclosures and selecting and applying accounting policies;
- Management did not identify controls over the accounting and classification of deferred research and development obligations - participation agreements; and
- Management did not identify controls over the valuation of stock-based compensation for option awards to employees and members of the board of directors.
Based on the assessment and identification of the material weaknesses described above, management has concluded that, as of June 30, 2023, our internal control over financial reporting was not effective and could lead to a material misstatement of account balances or disclosures. Accordingly, management has concluded that these control deficiencies constitute material weaknesses.
24
Table of Contents
However, after giving full consideration to these material weaknesses, and the additional analyses and other procedures that we performed to ensure that our consolidated financial statements included in this Quarterly Report on Form 10-Q were prepared in accordance with U.S. GAAP, our management has concluded that our consolidated financial statements present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.
Remediation Plan
Management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:
- Developing a training program and educating control owners concerning the principles of the Internal Control - Integrated Framework (2013) issued by COSO;
- Implementing a risk assessment process by which management identifies risks of misstatement related to all account balances;
- Developing internal controls documentation, including comprehensive accounting policies and procedures over financial processes and related disclosures;
- Enhancing policies and procedures to retain adequate documentary evidence for certain management review controls over certain business processes including precision of review and evidence of review procedures performed to demonstrate effective operation of such controls;
- Engaging outside resources for complex accounting matters and drafting and retaining position papers for all complex, non-recurring transactions;
- Developing monitoring activities and protocols that will allow us to timely assess the design and the operating effectiveness of controls over financial reporting and make necessary changes to the design of controls, if any;
- Segregating key functions within our financial and information technology processes supporting our internal controls over financial reporting;
- Reassessing and formalizing the design of certain accounting and information technology policies relating to security and change management controls, including user access reviews, including assessing the need for implementing a more robust information technology system; and
- Continuing to enhance and formalize our accounting, business operations, and information technology policies, procedures, and controls to achieve complete, accurate, and timely financial accounting, reporting and disclosures.
Changes in Internal Control Over Financial Reporting
Except for the remediation measures in connection with the material weaknesses described above, there were no other changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2023, that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
25
Table of Contents
Risk factors
As filed, 259 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes in our risk factors previously disclosed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022. You should carefully consider the risks and uncertainties described therein.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $4.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $4.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $701 | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $701 | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $3.3k | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $3.3k | us-gaap:GrossProfit |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $442.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $843.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$3.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $31.8k | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $34.8k | us-gaap:InterestExpense |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$2.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$4.0m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$3.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | At period end2023-06-30 | $530.1k | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $710.3k | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $3.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $3.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | −$3.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001654954-23-010769. Last ingested by Listed: Oct 24, 2026, 15:04 ET. Listed shows no prices and gives no investment advice.